ClinicalTrials.gg
Enrolling by invitationNCT06601803Updated Sep 19, 2024

Surgiphor Us in TSA

A Phase 4 interventional study of sterile saline solution and Surgiphor in Total Shoulder Arthroplasty, Shoulder Infection and Povidone Iodine, sponsored by Rothman Institute Orthopaedics. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Rothman Institute Orthopaedics · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as enrolling by invitation.
Phase
Phase 4
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Bacteria is occasionally present in the shoulder during shoulder arthroplasty surgery and is hypothesized to increase the risk of failure of the prosthesis. Surgiphor (sterile Povidone-Iodine) wound irrigation, is a solution used in orthopaedic surgery and other surgical fields to kill bacteria intraoperatively. The Iodine dissociates from complex and has antimicrobial properties, causing cell death of bacteria, fungi, and viruses through interactions with proteins, nucleotides, and fatty acids in the cytoplasm and cytoplasmic membrane.

This study examines the use of Povidone-Iodine during primary shoulder arthroplasty.

Read the detailed description

The purpose of this study is to determine the rate of reduction of positive cultures collected before and after wound irrigation with either Surgiphor or sterile normal saline during primary total shoulder arthroplasty

02

Conditions studied

  • Total Shoulder Arthroplasty
  • Shoulder Infection
  • Povidone Iodine
03

In context

Lead sponsor

Rothman Institute Orthopaedics is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults age >18 years
  • Participants undergoing elective primary total shoulder arthroplasty
  • Participants willing to provide written consent

Exclusion criteria

Exclusion Criteria:

  • History of prior surgery to the operative shoulder
  • Known allergy to povidone iodine, iodine or shellfish
  • active clinical infection
  • participation in other clinical trials
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
126 participants (estimated)

Study arms

  • Active comparator
    Total Shoulder Arthroplasty washed with Saline

    This arm will consist of sterile normal saline to be used before and after placement of shoulder arthroplasty components

    Drug: sterile saline solution · Procedure: Sample Collection

  • Active comparator
    Total Shoulder Arthroplasty washed with Surgiphor (Povidone Iodine)

    This arm will consist of Surgiphor to be used before and after placement of shoulder arthroplasty components

    Drug: Surgiphor · Procedure: Sample Collection

Interventions

  • Drugsterile saline solution

    The shoulder will be washed with normal sterile saline before and after placing the shoulder implant

  • DrugSurgiphor

    The shoulder will be washed with Surgiphor (Povidone Iodine) before and after placing the shoulder implant

  • ProcedureSample Collection

    During the surgical procedure, 4 swabs of the surgical wound will be taken at various times throughout the procedure

06

What researchers measure

Primary outcomes

  1. Reduction or elimination of bacteria

    To determine the rate of reduction of positive cultures collected before and after wound irrigation with either Surgiphor or sterile normal saline during primary total shoulder arthroplasty participants will be followed to watch for clinical signs of infection.

    Time frame: 90 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Sep 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2024
First posted
Sep 19, 2024
StartActual
Sep 16, 2024
Primary completionEst.
Sep 30, 2025
CompletionEst.
Sep 30, 2025
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06601803
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 16, 2024
Primary completion
Sep 30, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Sep 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion